Why did SANN.SW stock fall pre-market today?

SANN.SW stock fell **7.16%** pre-market largely due to profit-taking after recent gains, heavier-than-normal volume, and investor caution ahead of an April earnings update and clinical pipeline catalysts.

What is Meyka AI's forecast for SANN.SW stock?

Meyka AI's forecast model projects **CHF 16.49** in 12 months for SANN.SW stock, implying a **4.29%** upside from current **CHF 15.82**. Forecasts are model-based and not guarantees.

Is SANN.SW stock a buy after the drop?

SANN.SW stock may appeal to risk-tolerant investors given pipeline upside, but negative EPS **-5.38**, limited scale and binary clinical risks argue for caution and due diligence before buying.

What technical levels should traders watch for SANN.SW stock?

Traders should watch support near **CHF 15.48** (lower Bollinger band) and resistance near **CHF 17.27**. Relative volume and ADX suggest the current move has momentum, so tight stops are prudent.

CH Stocks

Down 7.16% pre-market on SIX: Santhera Pharmaceuticals (SANN.SW) CHF15.82 signals volatility and catalyst risk

ByHuzaifa Zahoor March 13, 2026

SANN.SW stock dropped 7.16% pre-market to CHF 15.82 on 13 Mar 2026 after opening at CHF 17.32 on the SIX exchange in Switzerland. The move makes Santhera Pharmaceuticals (SANN.SW) one of the early top losers, with volume at 197,234 shares versus a 50-day average of 106,706, a sign of heavier selling. Investors are pricing fresh uncertainty into the biotechnology name ahead of an April earnings announcement and while the healthcare sector has lagged the broader market this month.